Safety and efficacy of dupilumab in a patient with severe atopic dermatitis and HIV infection, with 15 months of follow-up

Clin Exp Dermatol. 2020 Aug;45(6):762-763. doi: 10.1111/ced.14278. Epub 2020 Jun 13.

Authors

M Romagnuolo¹, L Angileri¹, S Tavecchio¹, A V Marzano¹, S Ferrucci¹

Affiliation

¹ Dermatology Unit, Department of Pathophysiology and Transplantation, IRCCS Foundation Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

PMID: 32379943
DOI: 10.1111/ced.14278

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / pathology
Female
Follow-Up Studies
HIV Infections / complications*
Humans
Middle Aged
Quality of Life
Safety
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab